ADMA Biologics Statistics
Total Valuation
ADMA Biologics has a market cap or net worth of $5.31 billion. The enterprise value is $5.28 billion.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ADMA Biologics has 237.62 million shares outstanding. The number of shares has increased by 8.65% in one year.
| Current Share Class | 237.62M |
| Shares Outstanding | 237.62M |
| Shares Change (YoY) | +8.65% |
| Shares Change (QoQ) | +0.45% |
| Owned by Insiders (%) | 1.95% |
| Owned by Institutions (%) | 87.65% |
| Float | 232.87M |
Valuation Ratios
The trailing PE ratio is 27.57 and the forward PE ratio is 32.72.
| PE Ratio | 27.57 |
| Forward PE | 32.72 |
| PS Ratio | 12.20 |
| Forward PS | 10.58 |
| PB Ratio | 15.14 |
| P/TBV Ratio | 15.38 |
| P/FCF Ratio | 48.04 |
| P/OCF Ratio | 44.71 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 35.94, with an EV/FCF ratio of 47.85.
| EV / Earnings | 26.74 |
| EV / Sales | 12.39 |
| EV / EBITDA | 35.94 |
| EV / EBIT | 38.03 |
| EV / FCF | 47.85 |
Financial Position
The company has a current ratio of 5.97, with a Debt / Equity ratio of 0.24.
| Current Ratio | 5.97 |
| Quick Ratio | 2.76 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | 0.55 |
| Debt / FCF | 0.74 |
| Interest Coverage | 9.98 |
Financial Efficiency
Return on equity (ROE) is 81.65% and return on invested capital (ROIC) is 24.55%.
| Return on Equity (ROE) | 81.65% |
| Return on Assets (ROA) | 21.24% |
| Return on Invested Capital (ROIC) | 24.55% |
| Return on Capital Employed (ROCE) | 32.09% |
| Revenue Per Employee | $622,561 |
| Profits Per Employee | $288,574 |
| Employee Count | 685 |
| Asset Turnover | 1.04 |
| Inventory Turnover | 1.21 |
Taxes
| Income Tax | -71.96M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +241.44% in the last 52 weeks. The beta is 0.53, so ADMA Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.53 |
| 52-Week Price Change | +241.44% |
| 50-Day Moving Average | 18.47 |
| 200-Day Moving Average | 17.61 |
| Relative Strength Index (RSI) | 61.60 |
| Average Volume (20 Days) | 3,591,949 |
Short Selling Information
The latest short interest is 12.96 million, so 5.46% of the outstanding shares have been sold short.
| Short Interest | 12.96M |
| Short Previous Month | 15.07M |
| Short % of Shares Out | 5.46% |
| Short % of Float | 5.57% |
| Short Ratio (days to cover) | 3.58 |
Income Statement
In the last 12 months, ADMA Biologics had revenue of $426.45 million and earned $197.67 million in profits. Earnings per share was $0.81.
| Revenue | 426.45M |
| Gross Profit | 219.55M |
| Operating Income | 138.98M |
| Pretax Income | n/a |
| Net Income | 197.67M |
| EBITDA | 147.03M |
| EBIT | 138.98M |
| Earnings Per Share (EPS) | $0.81 |
Full Income StatementBalance Sheet
The company has $103.15 million in cash and $82.12 million in debt, giving a net cash position of $21.03 million or $0.09 per share.
| Cash & Cash Equivalents | 103.15M |
| Total Debt | 82.12M |
| Net Cash | 21.03M |
| Net Cash Per Share | $0.09 |
| Equity (Book Value) | 349.02M |
| Book Value Per Share | 1.48 |
| Working Capital | 275.87M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $118.67 million and capital expenditures -$8.23 million, giving a free cash flow of $110.45 million.
| Operating Cash Flow | 118.67M |
| Capital Expenditures | -8.23M |
| Free Cash Flow | 110.45M |
| FCF Per Share | $0.46 |
Full Cash Flow StatementMargins
Gross margin is 51.48%, with operating and profit margins of 32.59% and 46.35%.
| Gross Margin | 51.48% |
| Operating Margin | 32.59% |
| Pretax Margin | 29.48% |
| Profit Margin | 46.35% |
| EBITDA Margin | 34.48% |
| EBIT Margin | 32.59% |
| FCF Margin | 25.90% |
Dividends & Yields
ADMA Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.65% |
| Shareholder Yield | -8.65% |
| Earnings Yield | 3.73% |
| FCF Yield | 2.08% |
Analyst Forecast
The average price target for ADMA Biologics is $22.50, which is 0.76% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $22.50 |
| Price Target Difference | 0.76% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 19.77% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ADMA Biologics has an Altman Z-Score of 13.75 and a Piotroski F-Score of 7.
| Altman Z-Score | 13.75 |
| Piotroski F-Score | 7 |